Navigation Links
Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
Date:5/14/2008

in a prestigious, clinically oriented, peer-reviewed publication."

Results from Regado's 1c study were presented previously at the American Heart Association's 2007 Scientific Sessions.

About REG1 Anticoagulation System Clinical Program

In the Phase 1c clinical study, the researchers randomized 39 healthy volunteers to receive either three consecutive REG1 treatment cycles or placebo. Each REG1 cycle consisted of an intravenous (IV) bolus of RB006 dosed at 0.75 mg/kg, followed an hour later by a descending dose of RB007, ranging from a 2:1 to 0.125:1 antidote:drug ratio (1.5 mg/kg to 0.094 mg/kg of RB007). Clinical and coagulation assessments were measured for 14 days.

The Phase 1 program included two additional studies. A Phase 1a study enrolled 84 healthy volunteers, while a Phase 1b study enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. The results showed an IV bolus injection of RB006 achieved, in both study populations, a prompt, consistent, and dose-dependent prolongation of activated partial thromboplastin time (aPTT). In addition, a 1 mg/kg dose of RB006 resulted in essentially complete Factor IXa inhibition. The studies also demonstrated an IV bolus injection of RB007 administered in a 2:1 antidote:drug ratio successfully reversed prolonged aPTT within a median of one minute, with no rebound increase up to seven days. Despite dual antiplatelet use in 19 subjects, there were no major bleeding or other serious adverse events observed in either study.

Based upon the combined results of the Company's Phase 1a, 1b, and 1c studies, Regado initiated REVERSAL-PCI, a multi-center, open-label, randomized Phase 2a clinical study of the REG1 anticoagulation system. The Phase 2a study is enrolling 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon an
'/>"/>

SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
2. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
3. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING
4. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
5. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
6. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
11. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
(Date:7/24/2014)... July 24, 2014  ECC West Africa, LLC (ECC) ... with University College Hospital (UCH) Ibadan Board of ... to finance, design, construct, and operate and maintain a ... . Under the first of the 4-phase project, ... and funding applications. UCH Ibadan intends to finance and ...
(Date:7/24/2014)... research team led by group leader Yung-Eun Sung ... to synthesize sulfur-doped and nitrogen-doped graphenes which can ... batteries and fuel cells. Yung-Eun Sung is both ... Research at Institute for Basic Science* (IBS) and ... This achievement has great significance with regards to ...
(Date:7/24/2014)... Engineering at the University of Delaware, is known ... energy engineering, environmental sustainability and electronics. , His ... with a well-defined, crystalline structure. At the atomic ... that zeolites can separate molecules with size differences ... of a nanometer), making them useful to the ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2University of Delaware researcher describes new approach for creating organic zeolites 2
... 10 MedImmune today announced that,researchers will present ... the Annual Meeting of the American Association for,Cancer ... oncology research., "Cancer research has long been ... we,are proud to share data from our increasingly ...
... NEW YORK, April 10 Intellect Neurosciences,Inc. (OTC ... obtained a,Notice of Allowance and completed the grant ... Company,s ANTISENILIN(R) antibodies and,products being developed by the ... the European patent is expected in several weeks. ...
... (Nasdaq:,INSM), a developer of follow-on biologics and biopharmaceuticals, ... the Chairman and,Ranking Member of the U.S. House ... of legislation to establish a Follow-On,Biologics (FOBs) regulatory ... the biotechnology industry,healthcare and patient communities, the letter ...
Cached Biology Technology:MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research 2MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research 3Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 2Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 3Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 4Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 2Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 3
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
(Date:7/24/2014)... biodiversity, the product of 3.5 billion years of evolutionary ... of life. But it may be reaching a tipping ... and analysis of data published in Science , ... and decline of animals is contributing to what appears ... mass biological extinction event. , Since 1500, more than ...
(Date:7/24/2014)... Albert Einstein College of Medicine of Yeshiva ... Fox Foundation for Parkinson,s Research to translate a basic ... drug discovery project will test chemical compounds on a ... drug that acts on an underlying cause of the ... many people manage their symptoms, we are eager to ...
Breaking Biology News(10 mins):Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... a mathematical model of how cells pack together to form ... no model is universal. Researchers at Northwestern University have ... -- to show how cells pack together to create the ... hope that the pared-down equation can be applied to different ...
... Louis is partnering with Chrysler LLC and a ... if paint solid residues from automobile manufacturing can reduce ... project is based upon the technical expertise of Pratim ... Engineering Science, who has demonstrated the effectiveness of titanium ...
... Nucleonics, Inc., a privately held biotechnology company ... (RNAi)-based therapeutics, announced today that the company has ... safety study of its experimental treatment for chronic ... NUC B1000 ( http://www.nucleonicsinc.com/products/hepb.html ) is an ...
Cached Biology News:Researchers create mathematical model of fruit fly eyes 2Washington University, 2 industries, team to clean up mercury emissions 2Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 2Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 3
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... deparaffinize and perform Heat Induced Antigen Retrieval ... mounted on glass microscope slides. Deparffinization is ... high temperature used in HIER (over 90degrees ... by detergent. Formaldehyde fixation impairs or totally ...
... Calf Serum; U.S. sourced, ideal ... uncompromising quality; Low hemoglobin; Endotoxin: ... animals of US origin; U.S. ... seek an uncompromising quality. Low ...
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
Biology Products: